



# TOOLKIT FOR RESEARCH AND DEVELOPMENT OF PAEDIATRIC ANTIRETROVIRAL DRUGS AND FORMULATIONS

WHO and UNITAID

in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group





# TOOLKIT FOR RESEARCH AND DEVELOPMENT OF PAEDIATRIC ANTIRETROVIRAL DRUGS AND FORMULATIONS

WHO and UNITAID

in collaboration with IMPAACT (International Maternal Pediatric Adolescent AIDS Clinical Trials) network, PENTA (Paediatric European Network for Treatment of AIDS) foundation and experts from the Paediatric Antiretroviral Working Group



Toolkit for research and development of paediatric antiretroviral drugs and formulations

**ISBN 978-92-4-151436-1**

**© World Health Organization 2018**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Toolkit for research and development of paediatric antiretroviral drugs and formulations. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

The photographs in this material are used for illustrative purposes only; they do not imply any particular health status, attitudes, behaviors, or actions on the part of any person who appears in the photographs.

Photo credits:

Front and back covers: 1, ©WHO/Stéphane Saporito; 2, ©WHO/Christopher Black; 3, ©DNDi/Scholars & Gentlemen; 4, courtesy of Photoshare; 5, ©WHO/TDR /Andy Craggs; Inside cover, ©WHO/Anna Kari.

Page 5, ©WHO/Christopher Black; page 7, ©WHO/Christopher Black; page 12, ©WHO/Sergey Volkov; page 15, ©WHO/Christopher Black, page 32, ©WHO/Garry Smyth; page 38, Courtesy of Photoshare; page 51, ©ICAP/Sven Torfinn; page 67, ©WHO/Eduardo Soteras Jalil; page 72, Courtesy of Photoshare; page 79, ©WHO/SEARO/Gary Hampton; page 84, ©WHO/Sergey Volkov; page 110, Courtesy of Photoshare; page 114, ©WHO/Stéphane Saporito; page 126, ©DNDi/Scholars & Gentlemen; page 137, ©DNDi/Anita Khemka; page 144, ©WHO/Sergey Volkov; page 154 ©ICAP; page 164, ©Deidre Schoo; page 168, ©WHO/Petterik Wiggersn; page 177, Courtesy of Photoshare; page 184, ©WHO/Harry Anenden; page 191, ©WHO/TDR/Andy Craggs.

Layout: 400.co.uk

Printed in Switzerland

# CONTENTS

---

<b>Abbreviations</b> .....	iv
<b>Acknowledgements</b> .....	vi
<b>Introduction</b> .....	1
<b>Module 1: Trial design</b> .....	9
<b>Module 2: Pharmacokinetic modelling</b> .....	32
<b>Module 3: Pregnant and breastfeeding women</b> .....	45
<b>Module 4: Coinfections</b> .....	61
<b>Module 5: Acceptability</b> .....	78
<b>Module 6: Community engagement</b> .....	104
<b>Module 7: Target product profiles</b> .....	120
<b>Module 8: Product commercialization</b> .....	138
<b>Module 9: Regulatory filing</b> .....	148
<b>Module 10: Pharmacovigilance</b> .....	162
<b>Conclusion</b> .....	185

# ABBREVIATIONS

---

<b>3TC</b>	lamivudine
<b>ABC</b>	abacavir
<b>ART</b>	antiretroviral therapy
<b>ARV</b>	antiretroviral
<b>AUC24 h</b>	24-hour area under the concentration–time curve
<b>C24 h</b>	24-hour plasma concentration
<b>CL</b>	clearance
<b>CYP</b>	cytochrome 450
<b>DTG</b>	dolutegravir
<b>EFV</b>	efavirenz
<b>EMA</b>	European Medicines Agency
<b>EU</b>	European Union
<b>FDA</b>	United States Food and Drug Administration
<b>FTC</b>	emtricitabine
<b>HBV</b>	hepatitis B virus
<b>HCV</b>	hepatitis C virus
<b>IMPAACT</b>	International Maternal Pediatric Adolescent AIDS Clinical Trials
<b>LPV/r</b>	lopinavir/ritonavir
<b>NRTI</b>	nucleoside reverse-transcriptase inhibitor
<b>PANNA</b>	Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-Infected Pregnant Women
<b>PENPACT</b>	PENTA 9/PACTG 390
<b>PENTA</b>	Paediatric European Network for Treatment of AIDS
<b>PEPFAR</b>	United States President’s Emergency Plan for AIDS Relief
<b>TAF</b>	tenofovir alafenamide
<b>TB</b>	tuberculosis
<b>TDF</b>	tenofovir disoproxil fumarate
<b>UGT</b>	uridine diphosphate-glucuronosyltransferase
<b>UNICEF</b>	United Nations Children’s Fund
<b>WT</b>	body weight



©WHO/Christopher Black

# ACKNOWLEDGEMENTS

---

The toolkit for research and development of paediatric antiretroviral drugs and formulations was developed under the leadership of the Treatment and care team in the HIV Department, WHO, and supported by the WHO Paediatric Antiretroviral Working Group. The project was led by Martina Penazzato (WHO Paediatric HIV Lead, Geneva, Switzerland) and coordinated by Claire Townsend (WHO consultant, Geneva, Switzerland). Each module was drafted by one or more co-authors (listed in each module), with input from other collaborators and the project team. Designated reviewers reviewed the modules, including at least one member of the Paediatric Antiretroviral Working Group and one external reviewer. Input from representatives of drug manufacturers and regulatory authorities was sought at key stages.

WHO and Unitaid thank everyone who contributed to developing this toolkit, including individuals from the Clinton Health Access Initiative, Drugs for Neglected Diseases initiative, Medicines Patent Pool, ICAP at Columbia University, the European Paediatric Formulation Initiative and the IQ Consortium Drug Product Working Group.

Specifically, we thank the following individuals for their input: Elaine Abrams (ICAP at Columbia University, New York, NY, USA), Sharon Nachman (State University of New York at Stony Brook

States Food and Drug Administration or the European Medicines Agency, or members of the European Medicines Agency Paediatric Committee, are their own and may not be understood or quoted as being made on behalf of or reflecting the position of the United States Food and Drug Administration or of the European Medicines Agency or any of its committees or working parties.

The contents of this document do not necessarily reflect the official views of the United States Department of State.

The toolkit was developed with the financial support of Unitaid, the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network and the PENTA Foundation. The work of the Clinton Health Access Initiative on optimal antiretroviral drugs for children is made possible through the generous support of Unitaid.

## List of partner organizations

- International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network
- PENTA-ID Network
- Unitaid
- Drugs for Neglected Diseases initiative
- Clinton Health Access Initiative

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_25719](https://www.yunbaogao.cn/report/index/report?reportId=5_25719)

